1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Diabetic Neuropathy Industry: Forecasts to 2025

  • June 2017
  • 251 pages
  • ID: 5027981
In this report:
Increase in prevalence of diabetic neuropathy, advent of new therapeutics for treatment of neuropathy, favorable reimbursement scenario, and investment from key players in development of cost effective therapeutics for diabetic neuropathy are the major drivers of the global diabetic neuropathy market.

Summary

Table of Contents

Global Diabetic Neuropathy Market: Summary

The analysis on diabetic neuropathy market examines the current and future scenario of the overall market. Rise in prevalence of diabetic neuropathy, advent of additional therapeutics for treatment of neuropathy, favorable reimbursement scenario, and investment from key competitors in development of cost effective therapeutics for diabetic neuropathy are the main drivers of the overall diabetic neuropathy market.

The diabetic neuropathy market report comprises a detailed executive summary, which comprises a market snapshot that offers data about several segments of the market. It also offers info and data analysis of the overall diabetic neuropathy market with respect to the segments established on disorder type, treatment type, distribution channel and territory.

A in-depth qualitative analysis of drivers and restraints of the market and its opportunities has been specified in the market survey part. Additionally, the section comprises Porter's five forces analysis to comprehend the ambitious landscape in the sector. This section of the report also offers Analysis of market appeal, by area and market share review by top players, thus presenting a comprehensive study of the overall competitive scenario in the global diabetic neuropathy market.

Global Diabetic Neuropathy Market: Segmentation

Established on disorder type, the diabetic neuropathy market is broken down as peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy. The disorder type market segments have been examined based on available approved treatment for disorders and patient data. The market value and estimate for each of these segments have been provided for the time span from 2015 to 2025, together with their respective CAGRs for the outlook period from 2017 to 2025, considering 2016 as the base year.

Established on treatment type, diabetic neuropathy market is split into drugs, radiotherapy and physiotherapy. The drug segment is farther split into analgesic, antidepressant, anticonvulsant drugs and other drugs. The analgesic segment is farther split into topical, opioid, NSAIDs. The antidepressant segment is split into TCAs, SNRIs, and SSRIs. Radiotherapy segment is divided into Transcutaneous Electrical Nerve Stimulation, others.

The market segments have been comprehensively studied based on demand for available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each division have been provided for the time span from 2015 to 2025. The market research also offers the CAGR for each market segment for the estimate period from 2017 to 2025, considering 2016 as the base year.

Global Diabetic Neuropathy Market: Regional Analysis

Geographically, the overall diabetic neuropathy market has been classified into five main regions and the main countries in the respective region: North America continent, EU (the United Kingdom, Germany (DE), Russia, France (FR), Spain (ES), Italy (IT), and Rest of Europe (EU)), Asia-Pac (Japan (JP), India (IN), China (CN), Australia (AU) & New Zealand and Rest of Asia Pacific (APAC)), Latin America area (Brazil (BR), Mexico (MX), and Rest of Latin America area) and Middle East area & African continent (South Africa (ZA), GCC countries and Rest of Middle East (ME) & African continent).

The market value and estimate for each of these regions and the mentioned countries have been provided for the time span from 2015 to 2025, together with their respective CAGRs for the outlook period from 2017 to 2025, considering 2016 as the base year. The business research study also includes the ambitious scenario in these areas.

Global Diabetic Neuropathy Market: Competitive Analysis

The study also describes main actors in the overall diabetic neuropathy segment based on several features such as corporate overview and financial analysis, product portfolio, strategic management, and recent evolutions. Main actors described in this study include - Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Incorporated, Eli Lilly and Organization, GlaxoSmithKline plc, Pfizer, Incorporated, Lupin Limited, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd, Arbor Pharmaceuticals, LLC, Depomed, Incorporated, and others.

The Global Diabetic Neuropathy Market is broken down as given below:

Overall Diabetic Neuropathy Market, by Product

Overall Diabetic Neuropathy Market, by Treatment Type

Overall Diabetic Neuropathy Market, by Distribution Channel

Overall Diabetic Neuropathy Market, by Geography

North America (NA)

US

Canada (CA)

Europe (EU)

Germany (DE)

United Kingdom (UK)

Russia (RU)

Italy (IT)

France (FR)

Spain (ES)

Rest of europe (EU)

Asia-Pac

Japan (JP)

India (IN)

China (CN)

Australia & New Zealand

Rest of Asia Pacific (APAC)

Latin America

Brazil (BR)

Mexico (MX)

Rest of Latin America

African region & Middle East

GCC countries

South africa (SA)

Rest of African region and Middle East

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Essential Tremor Global Clinical Trials Review, H2, 2017

Clinical Research in Essential Tremor in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Essential Tremor Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Essential Tremor Global Clinical Trials Review, H2, 2017" provides an overview of Essential Tremo ...

Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017

Clinical Research in Globoid Cell Leukodystrophy (Krabbe Disease) in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, ...

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Clinical Research in Hepatic Encephalopathy in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.